Atrial Fibrillation: Closure of Left Atrial Appendage Not Superior to Blood Thinners

Atrial fibrillation, the most common heart rhythm disorder, affects an estimated 1.5 to 2 million people in Germany. While medications to prevent blood clots and subsequent stroke are standard treatment, a recent large-scale study challenges the routine use of a minimally invasive alternative – left atrial appendage closure – for patients at high risk of both stroke and bleeding. The findings, published in the New England Journal of Medicine, suggest the procedure doesn’t offer a clear benefit over carefully managed medication for this vulnerable group.

Understanding Atrial Fibrillation and Stroke Risk

Atrial fibrillation (AFib) occurs when the upper chambers of the heart beat irregularly and rapidly. This chaotic rhythm can allow blood to pool in the heart, particularly in a small pouch called the left atrial appendage. This pooling increases the risk of clot formation. If a clot travels to the brain, it can cause a stroke. The Deutsches Herzzentrum der Charité (DHZC) explains that preventing these clots is crucial in managing AFib.

The standard approach to stroke prevention in AFib is anticoagulation – using medications to thin the blood. While effective for many, these drugs carry a risk of bleeding, especially for individuals with pre-existing conditions like kidney problems or a history of bleeding. This is where left atrial appendage closure (LAAC) emerged as a potential alternative.

How Left Atrial Appendage Closure Works

LAAC involves implanting a device, known as an occluder, into the left atrial appendage via a catheter. This device permanently seals off the pouch, preventing clots from forming and migrating to the brain. Initially, patients require a short course of blood-thinning medication to prevent clots from forming *on* the device itself as it heals. After that, many can discontinue anticoagulation altogether. The procedure has gained traction, particularly for patients where the bleeding risks of long-term medication outweigh the benefits.

The CLOSURE-AF-DZHK16 Study: A Closer Look

To determine whether LAAC was at least as effective as modern, individualized medication management for patients with both high stroke and high bleeding risk, researchers conducted the CLOSURE-AF-DZHK16 study. Led by Professor Dr. Med. Ulf Landmesser of the DHZC, the study enrolled 912 patients with AFib across 42 specialized centers. All participants were deemed at high risk for both stroke and bleeding, representing a particularly challenging patient population.

Participants were randomly assigned to either undergo LAAC or receive optimized medical therapy – primarily with newer oral anticoagulants (NOACs) in over 80% of cases, when medically appropriate. The primary outcome measured was the occurrence of a composite endpoint: stroke, severe bleeding, or cardiovascular death. Patients were followed for a median of three years.

Study Findings: No Clear Advantage for LAAC

The study revealed that LAAC did not demonstrate a benefit over medical therapy. In fact, the rate of the combined outcome – stroke, severe bleeding, or cardiovascular death – was *higher* in the LAAC group compared to the medication group. This meant the study failed to demonstrate non-inferiority, a key goal of the research. The full study details are available in the New England Journal of Medicine.

“Our results show that we demand to make particularly differentiated decisions for patients with a incredibly high stroke and bleeding risk,” explains Professor Landmesser. “Left atrial appendage closure remains a relevant procedure that can reduce stroke risk. Yet, it is crucial to determine for which patient groups it actually provides an additional benefit. Further research is needed in this area.”

Implications for Clinical Practice and Future Research

These findings have significant implications for how clinicians approach stroke prevention in AFib patients. The study underscores the importance of individualized treatment decisions, carefully weighing the risks and benefits of both LAAC and anticoagulation. It suggests that LAAC should not be considered a routine alternative for all patients with high stroke and bleeding risk.

Professor Landmesser emphasizes the need for more precise risk stratification – identifying which patients are most likely to benefit from LAAC. “We need a more accurate assessment of risk in the future. The goal must be to tailor therapy more strongly – and to consider both stroke and bleeding risks equally.”

Understanding Risk Assessment: The CHA2DS2-VASc Score

Clinicians often use a scoring system called CHA2DS2-VASc to estimate stroke risk in AFib patients. This score considers factors like age, sex, history of stroke or TIA, heart failure, hypertension, diabetes, and vascular disease. A higher score indicates a greater risk of stroke and typically warrants anticoagulation. However, the study highlights that risk scores alone may not be sufficient to guide treatment decisions, particularly in patients with complex risk profiles.

What’s Next: Refining Patient Selection and Guidelines

The results of the CLOSURE-AF-DZHK16 study are expected to inform updates to clinical guidelines for AFib management. The findings will likely lead to more cautious recommendations regarding the use of LAAC in patients with high stroke and bleeding risk. Further research is needed to identify biomarkers or clinical characteristics that can predict which patients will respond best to LAAC. The German Heart Foundation provides additional information on atrial fibrillation and stroke prevention.

the goal is to provide the most effective and safest treatment for each individual patient, minimizing their risk of both stroke and bleeding. This requires a careful and individualized approach, informed by the latest evidence and a thorough understanding of the patient’s unique risk factors.